Invesco Ltd. Lyell Immunopharma, Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 405,949 shares of LYEL stock, worth $235,450. This represents 0.0% of its overall portfolio holdings.

Number of Shares

405,949

Previous 406,865 0.23%

Holding current value

$235,450

Previous $589,000 4.92%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$1.13 - $1.88 $1,035 - $1,722	-916 Reduced 0.23%	405,949 $560,000
Q2 2024 Aug 13, 2024	SELL	$1.3 - $3.01 $3,303 - $7,648	-2,541 Reduced 0.62%	406,865 $589,000
Q1 2024 May 14, 2024	BUY	$1.71 - $3.07 $168,087 - $301,771	98,297 Added 31.6%	409,406 $912,000
Q4 2023 Feb 12, 2024	BUY	$1.39 - $2.35 $25,571 - $43,232	18,397 Added 6.29%	311,109 $603,000
Q3 2023 Nov 13, 2023	BUY	$1.45 - $3.35 $2,973 - $6,870	2,051 Added 0.71%	292,712 $430,000
Q2 2023 Aug 11, 2023	BUY	$1.89 - $3.86 $2,787 - $5,693	1,475 Added 0.51%	290,661 $924,000
Q1 2023 May 12, 2023	BUY	$1.97 - $3.58 $460,022 - $835,980	233,514 Added 419.45%	289,186 $682,000
Q4 2022 Feb 13, 2023	SELL	$2.78 - $8.09 $709,800 - $2.07 Million	-255,324 Reduced 82.1%	55,672 $193,000
Q3 2022 Nov 14, 2022	BUY	$5.54 - $8.27 $1.41 Million - $2.11 Million	254,876 Added 454.16%	310,996 $2.28 Million
Q2 2022 Aug 15, 2022	SELL	$3.68 - $6.8 $9,435 - $17,435	-2,564 Reduced 4.37%	56,120 $366,000
Q1 2022 May 16, 2022	BUY	$5.05 - $7.7 $238,082 - $363,016	47,145 Added 408.57%	58,684 $296,000
Q4 2021 Feb 14, 2022	BUY	$7.13 - $15.19 $82,273 - $175,277	11,539 New	11,539 $89,000

Others Institutions Holding LYEL

# of Institutions

120

Shares Held

142M

Call Options Held

18.1K

Put Options Held

200

View Full List

About Lyell Immunopharma, Inc.

Ticker LYEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 247,824,992
Market Cap $144M
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...

More about LYEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account